Form 4: Director David Habiger Increases Stake in Boston Scientific

Boston Scientific Director David C. Habiger purchased 4,450 shares of common stock across two transactions in May 2026.

Summary

• Director David C. Habiger acquired 2,200 shares of common stock on May 19, 2026, at a weighted average price of $56.9451.
• Director David C. Habiger acquired an additional 2,250 shares of common stock on May 20, 2026, at a weighted average price of $55.9195.
• Following these transactions, the director's total beneficial ownership increased to 13,878 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying typically reflects internal confidence in the company's future performance.

Positives

• Insider confidence is demonstrated by the director's decision to increase his equity position in the company.
• The purchases were made at market prices, signaling alignment between the director and shareholder interests.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a disclosure of past insider transactions.

Industry Context

StockSavvy.ai notes that insider buying by board members is generally viewed as a positive signal of confidence in the company's long-term strategic direction and valuation.

Comparison to Industry Standards

• Insider buying is a standard practice among S&P 500 directors to demonstrate commitment to the firm.
• The volume of shares purchased is consistent with typical director-level equity accumulation patterns in large-cap medical device companies.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a sign of management stability and confidence.

Key Dates

Keywords

Boston Scientific, BSX, Insider Trading, Form 4, Director Purchase, Equity Ownership